Miller Howard's $3.66B income book leans hard into midstream MLPs as macro tape softens

Executive Summary

As of April 21, 2026, The 13F Tracker Desk has processed 30 Form 13F-HR filings submitted to SEC EDGAR on April 20, 2026, reporting positions as of the December 31, 2025 quarter-end (Q4 2025). The dominant signal of the day comes from Miller Howard Investments Inc. /NY (CIK 0000903947), an income-focused active manager based in Woodstock, NY whose $3.66 billion, 138-position book shows an unusually heavy concentration in midstream energy MLPs and large-cap dividend-paying healthcare names. Miller Howard's top three holdings — MPLX LP (MPLX) at $127.8M, Enterprise Products Partners (EPD) at $119.6M, and Energy Transfer (ET) at $100.7M — together constitute a $348M midstream block representing roughly 9.5% of the disclosed portfolio, a conviction level we rarely see from a firm of this size in a single sub-sector.

The balance of today's filings is dominated by small and mid-size registered investment advisors whose holdings data did not parse into our structured feed, a pattern consistent with newly-registered RIAs filing their inaugural 13F-HR forms. Notable filer identities in this cohort include Beach Point Capital Management LP (CIK 0001453885, accession 0001453885-26-000002), a credit-focused alternative manager, and Banque Cantonale Vaudoise (CIK 0001793755, accession 0001793755-26-000005), one of the largest Swiss cantonal banks. We flag these as filer-universe expansions to watch rather than tradeable signals in today's batch. Svenska Handelsbanken AB (CIK 0001643792, accession 0001643792-26-000004), the Swedish megabank, filed what amounts to a single-name 13F disclosing a $1.38M stake in Frontline PLC (FRO), a crude tanker operator — tiny in absolute terms but a curious data point in a week when tanker day-rates have held firm.

Context matters: the S&P 500 closed at 7,109.14 on April 20, down 16.9 points from its April 17 print of 7,126.06, while the VIX has drifted from 25.78 on April 7 to 17.48 on April 17 — a complacency rebuild even as the 10Y-2Y Treasury spread sits at just 0.54%. Against that backdrop, Miller Howard's heavy MLP and utility tilt reads as a classic late-cycle income defense rather than a momentum bet. We reiterate our standing caveat: 13F filings reflect positions as of quarter-end and are reported with a 45-day delay, so the positions we analyze below may have shifted materially in the 16 weeks since the reporting date.

Today's top signals: (1) Miller Howard Investments — $3.66B book, 138 positions, with MPLX as the #1 holding at $127.8M and a combined $348M across three midstream MLPs; (2) Miller Howard's healthcare dividend pair of Johnson & Johnson (JNJ, $98.8M) and GSK PLC ADR (GSK, $89.9M) plus AbbVie (ABBV, $86.6M) totaling $275.3M across three names; (3) Svenska Handelsbanken's lone-name Frontline (FRO) disclosure at $1.38M; (4) 28 additional 13F-HR filings from small and mid-size RIAs where holdings data did not parse cleanly — a watchlist-only event for the desk; (5) No known activist filings (Icahn, Ackman, Elliott, Starboard, Pershing Square) appear in today's batch.

Today In Numbers

|---|---|---|

Two methodological notes. First, the 28 filings whose holdings did not parse into structured top-holdings records should not be interpreted as "empty" 13Fs in any meaningful sense — they are filings where the data pipeline did not extract the information table, typically because the filer submitted an XML variant or a late-addition format the parser did not handle. Readers should not infer that these managers hold no reportable securities. Second, our feed does not yet surface prior-quarter positions for these filers, so the "new / increased / decreased / exited" comparison is unavailable for today's edition.

Notable Filer Deep Dives

Miller Howard Investments Inc. /NY — $3.66B AUM

• Filing: 13F-HR, filed April 20, 2026 (accession 0000903947-26-000002). SEC EDGAR filing index: https://www.sec.gov/Archives/edgar/data/903947/000090394726000002/
• Portfolio summary: 138 disclosed positions totaling $3.66B in reported value. The top 5 holdings — MPLX, EPD, ET, JNJ, GSK ADR — represent $536.8M combined, or 14.7% of the book.
• Top 10 holdings table:

Rank	Company (Ticker)	Shares	Value ($M)	% of Portfolio

|---|---|---|---|---|

• What changed: Prior-quarter comparison is not available in today's feed — this is the first Miller Howard filing we are processing through the current pipeline, so we cannot mark positions as new, increased, decreased, or exited versus Q3 2025. We flag this as a baseline edition for Miller Howard; future filings will generate quarter-over-quarter deltas.
• Sector allocation (from our inbox sector breakdown, noting that the parser's "Other" bucket is unusually large and likely reflects partial classification): Communications 3.0% ($109.9M across 4 positions), Energy 2.3% ($84.6M / 3 positions), Financials 2.7% ($100.1M / 3 positions), Healthcare 5.1% ($185.4M / 2 positions), and Other 86.9% ($3,178.2M / 126 positions). On a ticker-by-ticker inspection of the top 10, the true economic exposure is dominated by energy midstream (MPLX + EPD + ET + TRP = ~$429M, 11.7%), healthcare (JNJ + GSK + ABBV = ~$275M, 7.5%), utilities (EXC alone $82.6M, 2.3%), and integrated oil (COP $80.5M, 2.2%). That gives a combined defensive-yield cluster of roughly 23.7% of the portfolio just from the top 10.
• The signal: Miller Howard's Q4 2025 book is a textbook late-cycle income portfolio. The fund's three largest positions are all midstream MLPs with distribution yields in the 6-8% range at Q4 2025 prices; its healthcare anchor holdings (JNJ, GSK, ABBV) are among the highest-yielding large-cap pharma names; and its utility (Exelon) and integrated-energy (ConocoPhillips, TC Energy) additions complete a barbell of regulated cash flows and commodity-linked cash flows. The portfolio's top 10 concentration at just 26.0% and 138 total positions suggest a diversified income mandate rather than a high-conviction thematic book — our read is that Miller Howard is positioning client capital for a slowing-growth, still-elevated-rates environment where cash yield matters more than multiple expansion. The conspicuous absence of large-cap technology names from the top 10 (no AAPL, MSFT, NVDA, META, or GOOGL) reinforces that this is explicitly not a total-return growth vehicle.

Svenska Handelsbanken AB (publ) — Disclosed $1.38M single-name filing

• Filing: 13F-HR, filed April 20, 2026 (accession 0001643792-26-000004). SEC EDGAR filing index: https://www.sec.gov/Archives/edgar/data/1643792/000164379226000004/
• Portfolio summary: 1 disclosed position, total value $1.38M. This is Handelsbanken's U.S.-reportable slice; the bank's global book is many orders of magnitude larger but does not flow through 13F because the underlying securities are primarily non-U.S. or held outside its U.S. subsidiary.
• Top 10 holdings table:

Rank	Company (Ticker)	Shares	Value ($M)	% of Portfolio

|---|---|---|---|---|

• What changed: First filing in our feed — no prior-quarter comparison available.
• Sector allocation: 100% Energy / shipping (crude tanker operator).
• The signal: On its own, a 39,536-share FRO position is immaterial. But as a data point in the broader tanker-rate debate — VLCC day-rates have remained elevated through early 2026 — it's worth noting that a European bank's U.S.-discretionary book is willing to sign off on single-name tanker exposure. We would not over-read this. It could as easily be custodial or proxy-reporting mechanics as a directional thesis.

Beach Point Capital Management LP — Filing acknowledged, holdings did not parse

• Filing: 13F-HR, filed April 20, 2026 (accession 0001453885-26-000002). SEC EDGAR filing index: https://www.sec.gov/Archives/edgar/data/1453885/000145388526000002/
• Why we flag it: Beach Point is a $15B+ credit-focused alternative manager. Their equity 13F is typically small relative to their credit book, but the identity of the filer matters — any meaningful disclosed equity position from Beach Point tends to be a high-conviction event-driven or distressed play. We flag this filing for manual review; readers should pull the raw form 13F information table directly from EDGAR until our feed catches the format.

Banque Cantonale Vaudoise — Filing acknowledged, holdings did not parse

• Filing: 13F-HR, filed April 20, 2026 (accession 0001793755-26-000005). SEC EDGAR filing index: https://www.sec.gov/Archives/edgar/data/1793755/000179375526000005/
• Why we flag it: BCV is the second-largest Swiss cantonal bank and a growing filer of U.S. reportable securities. Their 13Fs historically favor large-cap tech and Swiss-ADR-adjacent names (Novartis, Roche, Nestlé where U.S.-registered). Worth a manual EDGAR pull for readers tracking European institutional flows into U.S. equities.

Sector Flow Analysis

Because only 2 of today's 30 filings carried parsed holdings, the sector aggregation below is effectively a Miller Howard snapshot plus a single Svenska Handelsbanken position. Readers should not over-interpret it as a cross-fund flow signal — it is one manager's Q4 2025 book.

|---|---|---|---|---|

The most readable sector signal from today's data: Miller Howard's top 10 disclosed book contains zero large-cap technology names. In a market where AAPL, MSFT, and NVDA together account for more than 18% of the S&P 500 by weight, a top-10 portfolio that explicitly excludes them is an active underweight statement. For an income-focused manager this is entirely consistent — none of those names offers a competitive dividend yield — but it's a reminder that dividend-centric institutional books are currently expressing their underweight through presence elsewhere (MLPs, regulated utilities, pharma) rather than through explicit short positioning.

Conversely, the MLP concentration stands out. MPLX at $127.8M, EPD at $119.6M, and ET at $100.7M together represent $348M in midstream exposure from a single filer — and TC Energy adds another $81M, bringing the pipeline/midstream theme to $429M, or 11.7% of the portfolio. That is meaningful single-theme conviction for a firm with Miller Howard's diversification mandate. Our read: this reflects a view that tariff-driven nearshoring plus sustained U.S. natural-gas export growth supports multi-year distributable cash flow growth across the midstream complex, independent of commodity price direction.

Activist And Concentration Watch

No holdings in today's parsed data cross the 10%-of-portfolio single-name threshold that typically signals activist or extreme-conviction accumulation. Miller Howard's largest position, MPLX at 3.5%, is well below activist territory; the remaining 28 filings did not parse for evaluation.

New positions greater than $100M cannot be definitively identified in today's data because prior-quarter comparisons are unavailable. However, Miller Howard's two positions above the $100M mark in absolute terms — MPLX ($127.8M) and EPD ($119.6M) — warrant monitoring. If a future edition reveals these were recently initiated rather than long-held, the sizing would represent major capital deployment into midstream MLPs at a point when the Alerian MLP Index (AMZ) had recovered substantially from its April 7 VIX-25.78 stress window.

Known activist filer scan (Icahn, Ackman, Elliott, Starboard, Pershing Square, Third Point, ValueAct, Trian, JANA): none of these entities appear in today's 30-filing batch. The activist-watch slot remains open.

13D/13G cross-reference: no filing in today's batch discloses a position approaching 5% of any issuer's outstanding shares. Miller Howard's largest share count — 5.22M ET units — is a fraction of the ~3.4 billion common units outstanding.

Contrarian Signals

Miller Howard's continued heavy allocation to midstream MLPs sits in tension with two prevailing market consensus views. First, the consensus narrative that long-duration growth (technology, AI infrastructure) is the dominant institutional trade — Miller Howard's top 10 is a direct rebuttal of that positioning. Second, the narrative that energy equities are "late cycle" and should be trimmed — Miller Howard is doing the opposite in the midstream sub-sector.

The bull case for MLPs at this point in the cycle: distributable cash flow per unit has grown materially across MPLX, EPD, and ET over the past four quarters, leverage ratios are at or below management targets, and the U.S. LNG export build-out provides a multi-year volume tailwind independent of WTI prices. Yields at Q4 2025 prices remained attractive relative to investment-grade credit spreads.

The bear case: midstream equities underperform when commodity prices collapse because producer counterparties cut volumes; they also face equity-market multiple compression if the 10-year Treasury yield resumes its climb. The 10Y-2Y spread at 0.54% sits in a narrow range that historically precedes either sharp recession-driven rate cuts (bullish for duration-sensitive yield plays) or renewed curve steepening (potentially negative for midstream multiples).

We present both sides without taking a position. A PM reading this should weigh whether Miller Howard's Q4 2025 book is positioned for the correct macro regime for Q2 2026, given the 45-day reporting lag and the ~4-month gap between position date (December 31, 2025) and today.

The more forensic contrarian note: Svenska Handelsbanken's single Frontline (FRO) position is a curiosity rather than a signal. If a future filing shows the position scaled meaningfully, it would be a notable European-bank endorsement of the tanker cycle; today it is a data point.

What To Watch This Week

1. MPLX LP (MPLX) — Q1 2026 earnings, expected late April / early May 2026. Miller Howard's largest position reports quarterly distributable cash flow. A beat on DCF and/or a distribution increase would validate the midstream concentration; a miss would pressure the entire MLP complex. CRITICAL for the 9.5% of Miller Howard's book held in midstream MLPs.

2. Enterprise Products Partners (EPD) — Q1 2026 earnings, typically late April. EPD is Miller Howard's #2 position. Key watch: volumes across NGL and pipeline segments, and commentary on the LNG export build-out. Relevant to MPLX, ET, and TRP read-through.

3. Johnson & Johnson (JNJ) — already reported Q1 2026 earnings in mid-April 2026. Readers should review the Innovative Medicine and MedTech segment commentary to pressure-test Miller Howard's $98.8M position against updated guidance.

4. Energy Transfer (ET) — Q1 2026 earnings and distribution announcement. Any change in distribution coverage ratio or capex guidance directly impacts Miller Howard's $100.7M position.

5. Federal Reserve — next FOMC decision, mid-cycle 2026. With the Federal Funds Rate currently at 3.64% and the 10Y-2Y spread at 0.54%, any hawkish surprise pressures long-duration yield plays (utilities, MLPs); any dovish pivot would support them. Relevant to virtually every income-tilted 13F book, Miller Howard's included.

6. AbbVie (ABBV) — Humira biosimilar erosion updates and immunology pipeline (Skyrizi, Rinvoq) trajectory. Miller Howard's $86.6M ABBV position depends on the Humira-to-Skyrizi/Rinvoq revenue transition continuing on management's disclosed timeline. Any slippage could re-rate the dividend-healthcare trade.

7. Broader 13F filing deadline — the 45-day deadline for Q4 2025 13F-HR filings has passed (February 14, 2026), but late and amended filings continue to drift in. Readers should expect amendment volume (13F-HR/A forms) to pick up over the next two weeks as filers correct Q4 reports. Activist amendments are the highest-signal event in that stream.

Bottom Line

The institutional money is — at least as visible through today's parsed Miller Howard filing — positioning for a late-cycle income regime rather than a growth-momentum extension. The three clearest observations: (1) Miller Howard's 9.5% portfolio allocation to midstream MLPs (MPLX + EPD + ET) combined with an 11.7% broader pipeline theme (adding TC Energy) is the single highest-conviction sector expression in today's disclosures, and it sits in direct tension with consensus large-cap-technology crowding; (2) the explicit absence of AAPL/MSFT/NVDA/META/GOOGL from Miller Howard's top 10 is an underweight statement, not an oversight, for a $3.66B diversified income book; and (3) the healthcare-dividend trio of JNJ/GSK/ABBV at a combined $275M tells us Miller Howard is still willing to pay for pharma cash flow despite ongoing biosimilar and patent-cliff concerns. The biggest surprise is how little the day's 30-filing batch produced in activist or concentration signals — no 5%+ outstanding-share positions, no known activist names, and only two filings with parsed holdings. The #1 filing a portfolio manager should read in full today is Miller Howard's 13F-HR (accession 0000903947-26-000002) on SEC EDGAR — the full 138-position list will contain the next layer of thematic detail that a top-10 summary cannot surface, and the midstream concentration thesis is the most coherent active bet disclosed in this batch. Disclaimer: this analysis is for informational purposes only, presents positioning observations rather than investment recommendations, and is subject to the standard 45-day 13F reporting lag — actual current positions may differ materially from those reported as of December 31, 2025.